


### Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

A is a bicyclic 6,5 or 6,6 aromatic or heteroaromatic group which is optionally substituted by 1 - 4 substituents, which substituents may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub>alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C<sub>1-6</sub>alkoxy, arylC<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkylC<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, C<sub>1-6</sub>alkylsulfonamido, C<sub>1-6</sub>alkylamido, arylsulfonamido, arylcarboxamido, aroyl, arylC<sub>1-6</sub>alkanoyl, and a group Ar<sup>1</sup>-B, wherein B represents a single bond, O, S or CH<sub>2</sub> and Ar<sup>1</sup> represents a phenyl or a monocyclic heteroaromatic group, said Ar<sup>1</sup> group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy or C<sub>1-6</sub>alkanoyl;

R<sub>1</sub> is hydrogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl or arylC<sub>1-6</sub>alkyl;

R<sub>2</sub> is independently halogen, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy;

p is 0, 1 or 2;

R<sub>3</sub> (a) is a group -(R<sub>4</sub>)<sub>r</sub> wherein R<sub>4</sub> is selected from the group consisting of: C<sub>1-6</sub>alkyl, halogen, hydroxy, oxo, cyano, nitro, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, arylC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfonyloxy, C<sub>1-4</sub>alkylsulfonylC<sub>1-4</sub>alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylsulfonamido, C<sub>1-4</sub>alkylamido, C<sub>1-4</sub>alkylsulfonamidoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylamidoC<sub>1-4</sub>alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-4</sub>alkyl, arylcarboxamidoC<sub>1-4</sub>alkyl, aroyl, aroylC<sub>1-4</sub>alkyl, arylC<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>acyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl and a group R<sub>30</sub>R<sub>31</sub>N- (where each of R<sub>30</sub> and R<sub>31</sub> independently represents a hydrogen atom or a C<sub>1-4</sub>alkyl group or where appropriate R<sub>30</sub>R<sub>31</sub> forms part of a C<sub>3-6</sub>azacycloalkane or C<sub>3-6</sub>(2-oxo)azacycloalkane ring), and r is 0, 1, 2 or 3; or

(b) forms a bridge across the ring, the bridge consisting of a chain of 1 to 3 atoms, the bridge being optionally substituted by one, two or three groups selected from halogen, oxo, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy; or


(c) is a chain of 1 to 3 atoms optionally substituted by halogen, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy, the other end of the chain being attached to an available carbon atom in Z;

X is CH, N or C;

$\text{---}$  represents a single bond when X is CH or N; and  $\text{=}$  represents a double bond when X is C;

q is 0, 1 or 2, wherein when q is 0, X is not N; and

Z is attached to the 6-position or the 8-position of the benzoxazinone group and is a 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)- or a




group

wherein m and n are independently 0, 1 or 2, and Y is a single bond, 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group,  $-(CH=CH)-$ ,  $-C(=O)-$ ,  $-C(=CH_2)-$ , oxygen, or a methylene group optionally substituted by one or two groups selected from halogen,  $C_1$ -6alkyl, cyano, halo $C_1$ -6alkyl,  $C_1$ -6alkanoyl,  $C_1$ -6alkoxy or hydroxy;

provided that when A is naphthyl, 5,6,7,8-tetrahydronaphthyl or 2,3-dihydroindene, Z is not  $-(CH_2CH(OH))-$ ,  $-(CH_2CH_2CH(OH))-$  or  $-(CH_2C(=O))$ .

2. (Original) A compound as claimed in claim 1, wherein A is a bicyclic 6,5 or 6,6 heteroaromatic group.

3. (Original ) A compound of formula (Ia) or a pharmaceutically acceptable salt thereof:



wherein:

A is a bicyclic 6,5 or 6,6 heteroaromatic group which is optionally substituted by 1 - 4 substituents, which substituents may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy,  $C_1$ -6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl,  $C_1$ -6alkoxy, aryl $C_1$ -6alkoxy,  $C_1$ -6alkylthio,  $C_1$ -6alkoxy $C_1$ -6alkyl,  $C_3$ -7cycloalkyl $C_1$ -6alkoxy,  $C_1$ -6alkanoyl,  $C_1$ -6alkoxycarbonyl,  $C_1$ -6alkylsulfonyl, arylsulfonyl, arylsulfonyloxy,  $C_1$ -6alkylsulfonamido,  $C_1$ -6alkylamido, Arylsulfonamido, arylcarboxamido, aroyl, aryl $C_1$ -6alkanoyl, and a group  $Ar^1$ -B, wherein B represents a single bond, O, S or  $CH_2$  and  $Ar^1$  represents a phenyl or a monocyclic heteroaromatic group, said  $Ar^1$  group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected

from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy or C<sub>1-6</sub>alkanoyl;

R<sub>1</sub> is hydrogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl or arylC<sub>1-6</sub>alkyl;

R<sub>2</sub> is independently halogen, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy;

p is 0, 1 or 2;

R<sub>3</sub> (a) is a group -(R<sub>4</sub>)<sub>r</sub> wherein R<sub>4</sub> is selected from the group consisting of: C<sub>1-6</sub>alkyl, halogen, hydroxy, oxo, cyano, nitro, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, arylC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkylC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfonyloxy, C<sub>1-4</sub>alkylsulfonylC<sub>1-4</sub>alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylsulfonamido, C<sub>1-4</sub>alkylamido, C<sub>1-4</sub>alkylsulfonamidoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylamidoC<sub>1-4</sub>alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-4</sub>alkyl, arylcarboxamidoC<sub>1-4</sub>alkyl, aroyl, aroylC<sub>1-4</sub>alkyl, arylC<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>acyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl and a group R<sub>30</sub>R<sub>31</sub>N- (where each of R<sub>30</sub> and R<sub>31</sub> independently represents a hydrogen atom or a C<sub>1-4</sub>alkyl group or where appropriate R<sub>30</sub>R<sub>31</sub> forms part of a C<sub>3-6</sub>azacycloalkane or C<sub>3-6</sub>(2-oxo)azacycloalkane ring), and r is 0, 1, 2 or 3; or

(b) forms a bridge across the ring, the bridge consisting of a chain of 1 to 3 atoms, the bridge being optionally substituted by one, two or three groups selected from halogen, oxo, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy; or


(c) is a chain of 1 to 3 atoms optionally substituted by halogen, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy, the other end of the chain being attached to an available carbon atom in Z;

X is CH, N or C;

$\text{—}$  represents a single bond when X is CH or N; and  $\text{=}$  represents a double bond when X is C;

q is 0, 1 or 2, wherein when q is 0, X is not N; and

Z is attached to the 6-position or the 8-position of the benzoxazinone group and is a 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group,  $-(CH=CH)-$  or a



group

wherein m and n are independently 0, 1 or 2, and Y is a single bond, 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group,  $-(CH=CH)-$ ,  $-C(=O)-$ ,  $-C(=CH_2)-$ , oxygen, or a methylene group optionally substituted by one or two groups selected from halogen,  $C_{1-6}$ alkyl, cyano, halo $C_{1-6}$ alkyl,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkoxy or hydroxy;

provided that when A is naphthyl, 5,6,7,8-tetrahydronaphthyl or 2,3-dihydroindene, Z is not  $-(CH_2CH(OH))-$ ,  $-(CH_2CH_2CH(OH))-$  or  $-(CH_2C(=O))$ .

4. (Currently Amended) A compound as claimed in ~~any of claims 1 to 3~~ claim 1, wherein R1 is hydrogen or methyl.
5. (Currently Amended) A compound as claimed in ~~any of claims 1 to 4~~ claim 1, wherein R3 is methyl.
6. (Currently Amended) A compound as claimed in ~~any of claims 1 to 5~~ claim 1, wherein X is CH or N and  $\equiv$  is a single bond.
7. (Currently Amended) A compound as claimed in ~~any of claims 1 to 6~~ claim 1, wherein q is 1.
8. (Currently Amended) A compound as claimed in ~~any of claims 1 to 7~~ claim 1, wherein Z is  $-(CH_2)_2-$  or  $-(CH_2)_3-$ .
9. (Currently Amended) A compound as claimed in ~~any of claims 1 to 8~~ claim 1, wherein A is indolyl, quinolyl, quinazolinyl or 2,3-dihydrobenzodioxinyl.

10. (Currently Amended) A compound as claimed in ~~any of claims 1 to 9~~ claim 1, wherein A is substituted by 1 to 4 substituents selected from the group consisting of halogen (particularly fluoro or chloro), C<sub>1-6</sub>alkyl (particularly methyl, ethyl and propyl), cyano, CF<sub>3</sub>, C<sub>1-6</sub>alkoxy (particularly methoxy, ethoxy or isopropoxy) or C<sub>1-6</sub>alkanoyl.

11. (Currently Amended) A compound as claimed in ~~any of claims 1 to 10~~ claim 10, wherein A is selected from the group consisting of 5-quinolyl(2-Me), 5-quinolyl(2-Me, 7-Cl), 5-quinolyl(2-Me, 7-F) and 5-quinazolinyl(2-Me), 5-quinolyl(2-Me, 7-Me), 5-dihydrobenzo[1,4]dioxinyl, 8-quinolyl(6-methoxy), 8-quinolyl, 4-indolyl and 4-indolyl(2-Me).

12. (Original) A compound as claimed in claim 1, which is selected from the group consisting of:

6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2,7-Dimethylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-[2-(4-Quinolin-4-yl)piperazin-1-yl]ethyl]-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinazolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(6-Methoxyquinolin-8-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-[2-(4-Quinolin-8-yl)piperazin-1-yl]ethyl]-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(1H-Indol-4-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-7-fluoro-4H-benzo[1,4]oxazin-3-one  
4-Methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4H-benzo[1,4]oxazin-3-one  
6-{1-Hydroxy-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one

6-{2-[3-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[2-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinolin-5-yl)-3,6-dihydro-2H-pyridin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinolin-5-yl)piperidin-1-yl]ethyl}-4-H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinolin-5-yl)-[1,4]diazepan-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinazolin-5-yl)-[1,4]diazepan-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
7-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{3-[4-(2-Methylquinolin-5-yl)-piperazin-1-yl]-propyl}-4H-benzo[1,4]-oxa-zin-3-one  
6-{3-[4-(7-Fluoro-2-methylquinolin-5-yl)piperazin-1-yl]-propyl}-4H-benzo-[1,4]oxazin-3-one  
6-{3-[4-(2-Methylquinolin-5-yl)-piperazin-1-yl]-propanoyl}-4H-benzo[1,4]-oxa-zin-3-one  
6-{1-Hydroxy-3-[4-(2-methylquinolin-5-yl)-piperazin-1-yl]-propyl}-4H-benzo-[1,4]oxazin-3-one  
6-{(E)-3-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]propenyl}-4H-benzo[1,4]-oxa-zin-3-one  
6-{4-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]butyl}-4H-benzo[1,4]oxazin-3-one  
6-{4-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]-cyclohex-1-enyl}-4H-benzo[1,4]-oxazin-3-one  
6-{4-[4-(2-Methylquinazolin-5-yl)piperazin-1-yl]butyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethoxy}-4-H-benzo[1,4]oxazin-3-one  
4-Methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethoxy}-4-H-benzo[1,4]oxazin-3-one  
7-Fluoro-6-{2-[4-(7-fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
6-{2-[4-(7-fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one  
7-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4H-benzo[1,4]oxazin-3-one  
6-{1-Hydroxy-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]-oxazin-3-one

6-{1-Methoxy-3-[4-(2-methylquinolin-5-yl)piperazin-1-yl]propyl}-4H-benzo[1,4]-oxazin-3-one

6-{2-[4-(2-Methyl-1H-indol-4-yl)piperazin-1-yl]-ethyl}-4H-benzo-[1,4]oxazin-3-one

6-{2-[4-(5,6,7,8-Tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl}-4H-benzo-[1,4]oxazin-3-one

6-[2-(4-Naphthalen-1-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one hydrochloride salt

6-{1-Fluoro-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]-oxazin-3-one

6-{1-Fluoro-3-[4-(2-methylquinolin-5-yl)piperazin-1-yl]propyl}-4H-benzo[1,4]-oxazin-3-one

5-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]-oxazin-3-one

5-Fluoro-4-methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]-oxazin-3-one

6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4-methyl-4H-benzo-[1,4]-oxazin-3-one

4-Ethyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1,4]-oxazin-3-one

6-{2-[4-(7-Fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4-methyl-4H-benzo-[1,4]-oxazin-3-one

6-{1-(Methoxy)-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{1-Amino-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

N-[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]acetamide

6-{1-(Methylamino)-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(phenyloxy)ethyl]-2H-1,4-benzoxazin-3(4H)-one

[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]formamide

6-{1-Hydroxy-1-methyl-3-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one



6-{1-Hydroxy-1-methyl-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-((1E)-1-Methyl-3-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]-1-propen-1-yl)-2H-1,4-benzoxazin-3(4H)-one  
6-(1-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}ethenyl)-2H-1,4-benzoxazin-3(4H)-one  
6-(1-{[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]methyl}ethenyl)-2H-1,4-benzoxazin-3(4H)-one  
2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl acetate  
6-{1-Hydroxy-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{[4-(8-Quinolinyl)-1-piperazinyl]methyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[(1S,4S)-5-(2-Methyl-5-quinolinyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(2-Quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{3-[4-(2-Quinolinyl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(6-Chloro-2-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(6-Nitro-2-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(7-Methyl-1,8-naphthyridin-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(1,6-Naphthyridin-5-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(2-Phenylquinolin-5-yl)piperazin-1-yl]ethyl}-4H-benzo[1.4]oxazin-3-one  
6-{[4-(7-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(7-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{1-Fluoro-2-[4-(7-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
8-Fluoro-6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
8-Fluoro-6-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2H-1,4-benzoxazin-3(4H)-one  
8-Fluoro-6-{1-hydroxy-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

8-Fluoro-6-{1-fluoro-2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

8-Fluoro-6-{2-[4-(7-fluoro-2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

8-Fluoro-6-{[4-(7-fluoro-2-methyl-5-quinoliny)-1-piperazinyl]acetyl}-2H-1,4-benzoxazin-3(4H)-one

8-Fluoro-6-{2-[4-(7-fluoro-2-methyl-5-quinoliny)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{[4-(8-Chloro-2-methyl-5-quinoliny)-1-piperazinyl]acetyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(8-Chloro-2-methyl-5-quinoliny)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(8-Chloro-2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

4-Methyl-8-{2-[4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

8-{2-[4-(2-Methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(7-Chloro-2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-7-fluoro-2H-1,4-benzoxazin-3(4H)-one

6-{2-[(2S)-2-Methyl-4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[(2R)-2-Methyl-4-(2-methyl-5-quinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(7-bromo-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{3-[4-(7-bromo-1H-indol-4-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(1-isoquinoliny)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

ethyl 5-{4-[2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]-1-piperazinyl}-1-benzofuran-2-carboxylate

6-{2-[4-(1,2-dihydro-5-acenaphthylenyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(5-chloro-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(6-chloro-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(7-chloro-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one

6-{3-[4-(5-chloro-1H-indol-4-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-({2-[4-(2-methyl-5-quinazoliny)-1-piperazinyl]ethyl}oxy)-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4H-benzo[1.4]oxazin-3-one

6-{2-[4-(7-Chloro-2-methyl-5-quinoliny)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(7-Chloro-2-methyl-5-quinoliny)-1-piperazinyl]-1-fluoroethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{3-[4-(2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

4-Methyl-6-{[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3,6-dihydro-1(2H)-pyridinyl]acetyl}-2H-1,4-benzoxazin-3(4H)-one

6-{1-hydroxy-2-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl}-4-methyl-2H-1,4-benzoxazin-3(4H)-one

6-{[4-(2-Methyl-5-quinoliny)-1-piperazinyl]methyl}-2H-1,4-benzoxazin-3(4H)-one

4-methyl-6-{[4-(2-methyl-5-quinoliny)-1-piperazinyl]acetyl}-3,4-dihydro-2H-1,4-benzoxazin-2-one

4-Methyl-6-(1-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]methyl}ethenyl)-3,4-dihydro-2H-1,4-benzoxazin-2-one

6-(2-Hydroxy-1-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]methyl}ethyl)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-one

6-{[4-(6-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{1-Hydroxy-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4-methyl-2H-1,4-benzoxazin-3(4H)-one

6-{[4-(8-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-4-methyl-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(8-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-4-methyl-2H-1,4-benzoxazin-3(4H)-one

6-{[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-4-methyl-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-4-methyl-2H-1,4-benzoxazin-3(4H)-one

4-Methyl-6-{2-[4-(2-methyl-5-quinolinyl)hexahydro-1H-1,4-diazepin-1-yl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

4-Methyl-6-{2-[3-methyl-4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{2-[4-(8-Chloro-2-methylquinolin-5-yl)-piperazine-1-yl]-ethyl}-4-methyl-4H-benzo[1,4]oxazine-3-one

6-{2-[4-(8-Fluoro-2-methyl-quinolin-5-yl)-piperazine-1-yl]-ethyl}-4-methyl-4H-benzo[1,4]oxazine-3-one

6-{2-[4-(2-Methyl-1H-indol-4-yl)piperazin-1-yl]ethanoyl}-4H-benzo[1,4]oxazin-3-one

6-{1-Hydroxy-2-[4-(2-methyl-1H-indol-4-yl)piperazinyl]ethyl}-2H-benzo[1,4]oxazin-3-one


6-{1-Fluoro-2-[4-(2-methyl-1H-indol-4-yl)piperazinyl]ethyl}-2H-benzo[1,4]oxazin-3-one

6-{2-[4-(7-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2-H-1,4-benzoxazin-3-(4H)-one

6-{2-[4-(2-Methyl-5quinolinyl)-1-piperadiny]-ethanoyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{1-Hydroxy-2-[4-(2-methyl-5quinolinyl)-1-piperadiny]-ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(7-Fluoro-2-methylquinolin-5-yl)piperidin-1-yl]ethyl}-4-H-benzo[1,4]-oxazin-3-one  
6-{2-[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperaziny]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one  
6{2-[4(8-Fluoro-2-methyl-5-quinolinyl)-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3-(4H)-one  
6-{2-[4-2-Quinoxaliny]-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3-(4H)-one  
4-Methyl-8-{2-[(2R)-2-methyl-4-(2-methyl-5-quinolinyl)-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
4-Methyl-8-{2-[(2S)-2-methyl-4-(2-methyl-5-quinolinyl)-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(7-Chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(7-Fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
6-{2-[4-(7-Bromo-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperaziny]ethyl}-2H-1,4-benzoxazin-3(4H)-one  
8-{4-[2-(3-Oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]-1-piperaziny}-2,3-dihydro-1,4-benzodioxin-6-carbonitrile  
and pharmaceutically acceptable salts thereof.


13. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II):



(II)


wherein R1, R2, p and Z are as defined in formula (I), and L is a leaving group, with a compound of formula (III):



(III)

wherein A, R3, ---, X and q are as defined in formula (I); or

(b) the reduction and concomitant cyclisation of a compound of formula (IV):



(IV)

in which A, X, R3, ---, q and Z are as defined in formula (I);

and optionally thereafter for each of process (a) or (b):


- removing any protecting groups, and/or
- converting a compound of formula (I) into another compound of formula (I), and/or
- forming a pharmaceutically acceptable salt.

14. (Currently Amended) A compound of formula (I) or formula (Ia) as defined in ~~any of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof, for use in therapy.

15. (Currently Amended) A pharmaceutical composition, which comprises a compound of formula (I) or formula (Ia) as defined in ~~any of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

16. (Currently Amended) A process for preparing a pharmaceutical composition as defined in claim 15, the process comprising mixing a compound of formula (I) or formula (Ia) as defined in ~~any of claims 1 to 12~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

17. (Original) A compound of formula (Ib) or a pharmaceutically acceptable salt thereof:



wherein:

A is a bicyclic 6,5 or 6,6 aromatic or heteroaromatic group which is optionally substituted by 1 - 4 substituents, which substituents may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub>alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C<sub>1-6</sub>alkoxy, arylC<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkoxyC<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkylC<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxycarbonyl, C<sub>1-6</sub>alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, C<sub>1-6</sub>alkylsulfonamido, C<sub>1-6</sub>alkylamido, arylsulfonamido, arylcarboxamido, aroyl, arylC<sub>1-6</sub>alkanoyl, and a group Ar<sup>1</sup>-B, wherein B represents a single bond, O, S or CH<sub>2</sub> and Ar<sup>1</sup>

represents a phenyl or a monocyclic heteroaromatic group, said Ar<sup>1</sup> group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy or C<sub>1-6</sub>alkanoyl;

R<sub>1</sub> is hydrogen, C<sub>1-6</sub>alkyl, haloC<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkylC<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl or arylC<sub>1-6</sub>alkyl;

R<sub>2</sub> is independently halogen, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy;

p is 0, 1 or 2;

R<sub>3</sub> (a) is a group -(R<sub>4</sub>)<sub>r</sub> wherein R<sub>4</sub> is selected from the group consisting of: C<sub>1-6</sub>alkyl, halogen, hydroxy, oxo, cyano, nitro, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, arylC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkylthio, hydroxyC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulfonyl, C<sub>1-4</sub>alkylsulfonyloxy, C<sub>1-4</sub>alkylsulfonylC<sub>1-4</sub>alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylsulfonamido, C<sub>1-4</sub>alkylamido, C<sub>1-4</sub>alkylsulfonamidoC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylamidoC<sub>1-4</sub>alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-4</sub>alkyl, arylcarboxamidoC<sub>1-4</sub>alkyl, aroyl, aroylC<sub>1-4</sub>alkyl, arylC<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>acyl, aryl, arylC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkyl and a group R<sub>30</sub>R<sub>31</sub>N- (where each of R<sub>30</sub> and R<sub>31</sub> independently represents a hydrogen atom or a C<sub>1-4</sub>alkyl group or where appropriate R<sub>30</sub>R<sub>31</sub> forms part of a C<sub>3-6</sub>azacycloalkane or C<sub>3-6</sub>(2-oxo)azacycloalkane ring), and r is 0, 1, 2 or 3; or

(b) forms a bridge across the ring, the bridge consisting of a chain of 1 to 3 atoms, the bridge being optionally substituted by one, two or three groups selected from halogen, oxo, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy; or

(c) is a chain of 1 to 3 atoms optionally substituted by halogen, C<sub>1-6</sub>alkyl, cyano, haloC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkoxy or hydroxy, the other end of the chain being attached to an available carbon atom in Z;


X is CH, N or C;

$\text{---}$  represents a single bond when X is CH or N; and  $\text{=}$  represents a double bond when X is C;



q is 0, 1 or 2, wherein when q is 0, X is not N; and

Z is attached to the 6-position or the 8-position of the benzoxazinone group and is a 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group,  $-(CH=CH)-$  or a



group

wherein m and n are independently 0, 1 or 2, and Y is a single bond, 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group,  $-(CH=CH)-$ ,  $-C(=O)-$ ,  $-C(=CH_2)-$ , oxygen, or a methylene group optionally substituted by one or two groups selected from halogen,  $C_{1-6}$ alkyl, cyano,  $haloC_{1-6}$ alkyl,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkoxy or hydroxy;

for use in the treatment of a serotonin-related disorder.

18. (Original) A compound as claimed in claim 17, wherein the disorder is depression or anxiety.

19. (Original) Use of a compound as defined in claim 17 in the preparation of a medicament for the treatment of a serotonin-related disorder.

20. (Original) The use as claimed in claim 19, wherein the disorder is depression or anxiety.

21. (Original) A method of treatment of a serotonin-related disorder, comprising administering to a mammal in need thereof a safe and effective amount of a compound as defined in claim 17.

22. (Original) The method as claimed in claim 21, wherein the disorder is depression or anxiety.